Previous close | 1.1800 |
Open | 1.1900 |
Bid | 1.2000 x 2200 |
Ask | 1.2100 x 1100 |
Day's range | 1.1800 - 1.2200 |
52-week range | 1.0700 - 4.3000 |
Volume | |
Avg. volume | 299,555 |
Market cap | 134.347M |
Beta (5Y monthly) | -0.22 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Shareholders might have noticed that OptiNose, Inc. ( NASDAQ:OPTN ) filed its quarterly result this time last week. The...
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
With a median price-to-sales (or "P/S") ratio of close to 3.1x in the Pharmaceuticals industry in the United States...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
To get a sense of who is truly in control of OptiNose, Inc. ( NASDAQ:OPTN ), it is important to understand the...
The latest analyst coverage could presage a bad day for OptiNose, Inc. ( NASDAQ:OPTN ), with the analysts making...
OptiNose ( NASDAQ:OPTN ) Third Quarter 2022 Results Key Financial Results Revenue: US$20.1m (down 8.0% from 3Q 2021...
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
We feel now is a pretty good time to analyse OptiNose, Inc.'s ( NASDAQ:OPTN ) business as it appears the company may be...
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.